Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of “Buy” by Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given an average rating of “Buy” by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $32.50.

A number of research firms have issued reports on CPRX. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Bank of America reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Finally, Robert W. Baird raised their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 3rd.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $21.02 on Monday. The stock has a market capitalization of $2.55 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals has a 1 year low of $14.47 and a 1 year high of $24.64. The stock’s fifty day moving average is $22.26 and its two-hundred day moving average is $21.53.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. The trade was a 25.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $29,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $3,733,000. Armis Advisers LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $306,000. Mackenzie Financial Corp increased its position in shares of Catalyst Pharmaceuticals by 132.9% during the fourth quarter. Mackenzie Financial Corp now owns 34,531 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 19,705 shares during the period. Finally, Castlekeep Investment Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $1,775,000. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.